Chemo plus immunotherapy before surgery for bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy, an immunotherapy drug (adebrelimab), and a drug to boost white blood cells (mecapegfilgrastim) before surgery for people with biliary tract cancer. The goal is to see if this approach can shrink the tumor enough to make surgery possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with biliary tract cancer (bile duct or gallbladder cancer) that has not spread widely and may be removed with surgery, but it is currently too difficult to remove directly.
- You have not received any previous treatment for this cancer.
- You are able to perform daily activities with little to no help (ECOG 0 or 1).
- You do not have a serious allergy to monoclonal antibody drugs, and you do not have an active autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests adding the immunotherapy adebrelimab to standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for advanced biliary tract cancer that can't be removed by surgery. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a combination of an immunotherapy (adebrelimab), a targeted therapy (apatinib), and two chemotherapy drugs (gemcitabine and cisplatin) given before surgery for biliary tract cancers that are removable but at high risk of coming back. The goal is to see if this approach helps shrink the tumor and improve outcomes after surgery.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) and an immunotherapy drug (pembrolizumab) given before and after surgery for people with bile duct or gallbladder cancer that can be removed. The goal is to see if this approach helps prevent the cancer from coming back.
This trial tests a combination of chemotherapy and immunotherapy before surgery for locally advanced bile duct cancer. The goal is to see if this approach can shrink the tumor enough to improve surgical outcomes.
This trial tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) plus an immunotherapy drug (envafolimab) for biliary tract cancer that can be removed by surgery. The goal is to prevent cancer from coming back after surgery.
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted therapy (apatinib) before and after surgery for bile duct cancer that can be removed and has a high risk of coming back. It aims to see if this approach can lower the chance of recurrence.
Hear when a new Biliary Tract Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.